title: Modulation of central glucocorticoid receptors in short- and long-term experimental hyperthyroidism.
abstract: Hyperthyroidism is associated with a significant increase in circulating glucocorticoid levels and hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis. The aim of this study was to examine whether the HPA axis hyperactivity observed in hyperthyroidism may be explained by a disturbed feedback inhibition of endogenous glucocorticoids through two specific intracellular receptors in the brain: the high affinity mineralocorticoid receptor (MR) and the lower affinity glucocorticoid receptor (GR). Cytosolic receptor binding and gene expression was assessed in rats with short (7 days) and long standing (60 days) eu- and hyperthyroidism. Glucocorticoid receptor number and binding affinity (Kd) in the hippocampus were measured using [(3)H2]-dexamethasone radioreceptor assay. In situ hybridization was employed to examine the effects of hyperthyroidism on the GR and MR mRNA levels in the hippocampus and the pituitary. Both short- and long-term hyperthyroid rats showed pronounced reduction in the concentration of cytosolic GR in the hippocampus, without changes in binding affinity or changes in GR expression. In contrast, GR mRNA in the pituitary increased after 7 days and decreased after 60 days of thyroxin treatment. MR mRNA was moderately affected. Hyperthyroidism is associated with significant decreases in hippocampal GR levels supporting the hypothesis that hyperactivity of the HPA axis observed in experimentally induced hyperthyroidism may be attributed, at least in part, to decreased negative feedback at the level of the hippocampus. These findings further support the notion that a central locus is principally responsible for the hyperactivity of the HPA axis observed in hyperthyroidism.
authors.affiliation: Department of Anatomy, School of Medicine, University of Athens, 75 Mikras Asias Str., Goudi, 11572, Athens, Greece.
authors.forename: Elena
authors.initials: E
authors.lastname: Nikolopoulou
authors.forename: Dimitrios
authors.initials: D
authors.lastname: Mytilinaios
authors.forename: Aldo E
authors.initials: AE
authors.lastname: Calogero
authors.forename: Themis C
authors.initials: TC
authors.lastname: Kamilaris
authors.forename: Theodore
authors.initials: T
authors.lastname: Troupis
authors.forename: George P
authors.initials: GP
authors.lastname: Chrousos
authors.forename: Elizabeth O
authors.initials: EO
authors.lastname: Johnson
mesh_terms: D000208:Acute Disease; D000818:Animals; D002908:Chronic Disease; D003600:Cytosol / Q000378:metabolism; D015870:Gene Expression / Q000235:genetics; D006624:Hippocampus / Q000187:drug effects / Q000378:metabolism; D006980:Hyperthyroidism / Q000378:metabolism*; D007030:Hypothalamo-Hypophyseal System / Q000378:metabolism; D008297:Male; D010903:Pituitary Gland, Anterior / Q000187:drug effects / Q000378:metabolism; D010913:Pituitary-Adrenal System / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D011965:Receptors, Glucocorticoid / Q000096:biosynthesis / Q000235:genetics / Q000378:metabolism*; D018161:Receptors, Mineralocorticoid / Q000378:metabolism; D012462:Saline Solution, Hypertonic; D013974:Thyroxine / Q000494:pharmacology
chemical_list: D011965:Receptors, Glucocorticoid; D018161:Receptors, Mineralocorticoid; D012462:Saline Solution, Hypertonic; D013974:Thyroxine